Synnovation Therapeutics

Executive Summary

Synnovation Therapeutics is a US-based precision oncology company founded in 2021, focused on developing small molecule therapies for genetically defined patient populations. By integrating genetics and genomics insights, the company aims to deliver targeted treatments with improved efficacy and safety profiles. With $102 million raised to date, Synnovation is advancing its pipeline of novel small molecule inhibitors, targeting specific oncogenic alterations. The company's approach aligns with the broader trend toward personalized medicine, potentially offering differentiated therapies for patients with well-characterized genetic mutations. Currently in Phase 1 clinical development, Synnovation is poised to generate initial proof-of-concept data that could validate its platform and support further investment. The company's strong financial backing and focus on high-value targets suggest a solid foundation for growth, though early-stage clinical risk remains elevated.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 safety and preliminary efficacy data readout for lead asset40% success
• Q4 2026Initiation of Phase 1b/2 expansion cohort for second program50% success
• TBDPotential strategic partnership or licensing deal30% success